Search for: "Astrazeneca"
Results 41 - 60
of 1,244
Sort by Relevance
|
Sort by Date
25 Apr 2023, 9:08 am
#LegalTweetoftheDay: Pharmacist ran $6.5M scheme against AstraZeneca before allegedly fleeing Canada, ruling finds #law #legal #lawtwitter via @CTVNews https://bit.ly/4468s5Z - Garry J. [read post]
18 Mar 2023, 12:53 pm
AstraZeneca UK Ltd., 22 F.4th 204, 231–32 (D.C. [read post]
14 Mar 2023, 4:09 pm
Kimberly Braslow, Patent Director, AstraZeneca, and Vice Chair, AIPLA Food and Drug Committee. [read post]
1 Mar 2023, 1:00 am
The application was rejected by the Swedish Intellectual Property Office, and the appeal by AstraZeneca dismissed by the Patent and Market Court.The Patent and Market Court of Appeal again dismissed the appeal. [read post]
25 Feb 2023, 3:44 am
AstraZeneca S.A. appealed the order arguing that the information was protected by commercial secrecy and that its disclosure could harm the acquisition and delivery of vaccines. [read post]
13 Feb 2023, 4:00 pm
Qualified or Part-Qualified European Patent Attorney in Gothenburg/SwedenAt AstraZeneca, we turn ideas into life-changing medicines. [read post]
7 Feb 2023, 11:08 am
To be sure, not all COVID-related suits against vaccine development companies have succeeded; the case against AstraZeneca, which was dismissed, related to the company’s efforts to develop a COVID-19 vaccine. [read post]
5 Feb 2023, 3:51 pm
AstraZeneca won in the District of Delaware, while Sanofi Aventis and Novo Nordisk lost at the District of New Jersey. [read post]
31 Jan 2023, 10:19 am
Although Merpel wonders why the offers were not also made under Part 36, the Judge nevertheless decided that the refusal of the offers by ONI was not "highly unreasonable" (as is the test under see White Book CPR 44.3.12, F & C Alternative Investments (Holdings) v Barthelemy [2012] EWCA Civ 843 at [70] (citing Kiam v MGM), Astex Therapeutics v AstraZeneca [2018] EWCA Civ 2444 at [61]-[78]). [read post]
27 Jan 2023, 6:00 am
For example, instructions on the label of the AstraZeneca (AZ) COVID-19 vaccine in South Korea read “not recommended for those under the age of 30,” which led many people to ask the authorities whether this referred to “Korean age” or “international age. [read post]
26 Jan 2023, 9:15 am
Bristol Myers claimed AstraZeneca’s Imjudo cancer treatment infringes on its patent and that AstraZeneca failed to first obtain a license or permission. [read post]
26 Jan 2023, 9:15 am
Bristol Myers claimed AstraZeneca’s Imjudo cancer treatment infringes on its patent and that AstraZeneca failed to first obtain a license or permission. [read post]
17 Jan 2023, 5:00 am
As of December 15, 2022, only 34% of the population in Africa has received at least one dose of the COVID-19 vaccine, with Moderna and BioNTech having provided fewer doses compared to Oxford-AstraZeneca and Johnson & Johnson. [read post]
6 Jan 2023, 2:33 pm
In 2015, AstraZeneca and Cephalon paid a total of $54 million to resolve claims that they also improperly reduced AMPs by wrongfully accounting for service fees they paid to wholesalers. [read post]
3 Jan 2023, 1:47 pm
The directors’ and officers’ liability environment is always changing, but 2022 was a particularly eventful year, with important consequences for the D&O insurance marketplace. [read post]
27 Dec 2022, 4:33 pm
The rejection of this SPC application was appealed by AstraZeneca, but the appeal was rejected by the Patent and Market Court and subsequently by the Patent and Market Court of Appeal with decision PMÖÄ 1213-20 of April 7, 2021 (PDF version; rough English machine translation). [read post]
14 Dec 2022, 1:23 pm
Nevertheless, the extent to which the dismissal motions that have been ruled upon have been granted is noteworthy — dismissal motions have been granted in a number of COVID-19 related cases, including, for example, the cases pending against the cruise ship lines (as discussed, for example, here); as well as in cases filed against, among others, AstraZeneca (here); Sorrento Therapeutics (here); The Geo Group (here); and Velocity Financial (here). [read post]
14 Dec 2022, 12:00 am
In this article, we address these questions by drawing on our first-hand experience of shaping and driving the roll-out of AI governance within AstraZeneca, a biopharmaceutical company. [read post]
14 Oct 2022, 5:16 am
Outsource or Die The rising costs and complexity of commercializing various drugs have pushed most drug companies—such as AstraZeneca—to restructure their drug-making process from a fully integrated, in-house operation to one leveraging the outsourcing of noncore functions. [read post]
15 Sep 2022, 1:47 pm
Background In April 2020, AstraZeneca announced a partnership with Oxford to develop a COVID-19 vaccine candidate known as AZD1222. [read post]
